Longitudinal analysis reveals that a personalized plasma cfDNA assay enhances MRD detection, indicating improved relapse monitoring in AML patients post-alloHCT.
Key Points
MRD detection was 100% sensitive with a plasma-based assay, compared to 13.3% with conventional methods.
Among AML patients evaluated, plasma cfDNA showed a 69.2% positivity rate for MRD at 3 months post-alloHCT.
The duplex sequencing assay revealed that the inclusion of multiple genetic mutations significantly improved MRD sensitivity.
These findings suggest that plasma cfDNA monitoring may facilitate better post-transplant care and reduce reliance on biopsies.